Biopharma & Life Sciences
REGENXBIO Inc. Executive Compensation (FY25)
RGNX · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Curran Simpson | Latest say-on-pay support = May 29, 2026 |
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The paid brief on REGENXBIO Inc.
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Data as of October 22, 2026Latest filing (8-K): June 3, 2026
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Member, one year
261 figures on this page: 253 cited to the filing that reported them, 8 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
More on REGENXBIO Inc.
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Curran Simpson: $4,784,543 → $4,200,712 (12.2% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is REGENXBIO Inc.'s chief executive and what were they paid?
Curran Simpson was paid $4,200,712 in total compensation as President and Chief Executive Officer for fiscal 2025. Compared with the $4,784,543 reported for fiscal 2024, Simpson's total was 12.2% lower.
What was REGENXBIO Inc.'s say-on-pay result?
For fiscal 2025, the say-on-pay proposal drew 92.3% support at the meeting held May 29, 2026.
Which companies are in REGENXBIO Inc.'s peer group?
The disclosed peer group names Agios Pharmaceuticals, Inc., bluebird bio, Inc., Blueprint Medicines Corporation, CRISPR Therapeutics AG and Denali Therapeutics Inc., among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Kenneth Mills President and CEO | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Olivier Danos EVP, Chief Scientific Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Curran Simpson EVP, Chief Operating Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Stephen Pakola EVP, Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Vit Vasista EVP, Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Kenneth Mills Former President | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Stephen Pakola EVP, Chief Medical | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Olivier Danos EVP, Chief Scientific | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Curran Simpson President and CEO | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Vit Vasista Former EVP, Chief | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Kenneth Mills Former President and CEO Departed during or after this year | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Curran Simpson President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Mitchell Chan EVP, Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Olivier Danos EVP, Chief Scientific Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Patrick Christmas EVP, Chief Strategy and Legal Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Stephen Pakola EVP, Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Vit Vasista Former EVP, Chief Financial Officer Departed during or after this year | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Curran Simpson President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Patrick Christmas EVP, Chief Strategy and Legal Officer | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | ◇ |
Stephen Pakola EVP, Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Curran Simpson | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Patrick J. Christmas | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Stephen Pakola | RSU | ◇ | — | — | ◇ | — | — | ◇ |
Fiscal 2022, 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Curran Simpson | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/2/2035 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/3/2033 | |
| Option | ◇ | — | ◇ | 7/1/2034 | |
| Option | ◇ | — | ◇ | 1/3/2032 | |
| Option | ◇ | — | ◇ | 1/2/2034 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Patrick Christmas | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 1/2/2034 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/3/2032 | |
| Option | ◇ | — | ◇ | 1/3/2033 | |
| Option | ◇ | — | ◇ | 1/2/2035 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Stephen Pakola | Option | ◇ | — | ◇ | 1/3/2032 |
| Option | ◇ | — | ◇ | 1/2/2035 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/3/2033 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/2/2034 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Daniel Tassé Lead independent director | ◇ | ◇ | ◇ | — | — | — | ◇ |
Kenneth T. Mills Board chair | ◇ | ◇ | ◇ | — | — | — | ◇ |
George Migausky | ◇ | ◇ | ◇ | — | — | — | ◇ |
David C. Stump | ◇ | ◇ | ◇ | — | — | — | ◇ |
Jennifer Zachary | ◇ | ◇ | ◇ | — | — | — | ◇ |
A.N. Jerry Karabelas | ◇ | ◇ | ◇ | — | — | — | ◇ |
Alexandra Glucksmann | ◇ | ◇ | ◇ | — | — | — | ◇ |
Jean Bennett | ◇ | ◇ | ◇ | — | — | — | ◇ |
Allan M. Fox | ◇ | ◇ | ◇ | — | — | — | ◇ |
Curran Simpson served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options and RSUs.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
- Agios Pharmaceuticals, Inc. AGIO
- bluebird bio, Inc. BLUE
- Blueprint Medicines Corporation BPMC
- CRISPR Therapeutics AG CRSP
- Denali Therapeutics Inc. DNLI
- Editas Medicine, Inc. EDIT
- MacroGenics, Inc. MGNX
- Mirati Therapeutics, Inc. MRTX
- PTC Therapeutics, Inc. PTCT
- Sangamo Therapeutics, Inc. SGMO
- Supernus Pharmaceuticals, Inc. SUPN
- Ultragenyx Pharmaceutical Inc. RARE
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 29, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 30, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 31, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 2, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 3, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | June 4, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | May 29, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | May 31, 2019 | = | ◇ | ◇ | ◇ |
Velarion Pro: every company page, peer tools and exports, one seat
One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Curran Simpson (President and Chief Executive Officer), FY2025 total compensation $4,200,712 (base salary $665,510) [exec_comp, SEC accession 0001193125-26-155058, filed 2026-04-14]What this page does not include
Everything above is a fact REGENXBIO Inc. disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where REGENXBIO Inc. sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
261 figures on this page: 253 cited to the filing that reported them, 8 calculated from figures it prints.
253 cited to the filing
8 calculated from the filing
Documents cited
- 0001193125-26-254590Proposal 3 : By the following vote, the stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement: Votes For Votes Ag
- 0001193125-26-1550582025 Director Compensation Table · DIRECTOR COMPENSATION · Outstanding Equity Awards at 2025 Fiscal Year-End · Summary Compensation Table
- 0000950170-25-080986Proposal 3 : By the following vote, the stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement: Votes For Votes Ag
- 0000950170-25-052069
- 0000950170-24-068050Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-23-026437Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-22-168821Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001564590-21-031957Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-20-157279Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-19-164137Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “REGENXBIO Inc. executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/RGNX (accessed 2026).
Short form: data: Velarion
The paid brief for REGENXBIO Inc.
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about REGENXBIO Inc. and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers REGENXBIO Inc. discloses
The companies named in RGNX's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}